Biology’s most important targets are still out of reach
Biology’s most important targets are still out of reach
We’re pioneering a new modality to unlock them
We’re pioneering a new modality
to unlock them
Our supporters
Our supporters
What we do
What we do
For decades, drug discovery has focused on the ~20% of targets accessible to conventional therapies: proteins on the cell surface or with well-defined binding pockets.
The remaining 80% of human biology has been out of reach. Many targets are hidden within the cell and are structurally too complex for traditional drug discovery, yet they drive diseases such as cancer, autoimmunity, and neurodegeneration.
We teach patient’s immune cells to make and deliver therapeutic proteins designed to engage these “undruggable” targets. Leveraging generative AI and synthetic biology, our platform optimises therapeutic design for in situ expression and activity, unlocking disease targets that have remained inaccessible to medicine until now.
For decades, drug discovery has focused on the ~20% of targets accessible to conventional therapies: proteins on the cell surface or with well-defined binding pockets.
The remaining 80% of human biology has been out of reach. Many targets are hidden within the cell and are structurally too complex for traditional drug discovery, yet they drive diseases such as cancer, autoimmunity, and neurodegeneration.
We teach patient’s immune cells to make and deliver therapeutic proteins designed to engage these “undruggable” targets. Leveraging generative AI and synthetic biology, our platform optimises therapeutic design for in situ expression and activity, unlocking disease targets that have remained inaccessible to medicine until now.
